On this episode of The Tatiana Show, Tatiana and Josh speak with our returning guest, Kevin McKernan, about how he combatted hacked servers and secured his Medicinal Cannabis Genomics data using encrypted blockchain technology. These so-called “Honey Pot” data servers were trusted until they implemented their premeditated plan to steal their customers data in order to use it for competitive advantage. We also hear more about the newest science behind Cannabis Genetics – such as a brewing technique that integrates cannabis within a yeast strain. Stay tuned to learn the surprising bit about how psychoactive compounds are made – not grown organically. McKernan is an expert in the field of Cannabis Genomics and we are excited to share his amazing journey through one of the fastest-growing industries with our listeners. As always, thank you to our sponsors Vaultoro and SALT Lending. Cheers!
About the Guests:
Kevin is the CSO and Founder of Medicinal Genomics and has pioneered the genomics of cannabis and hemp to build a stronger scientific environment (Kannapedia.net) for the study of cannabis based therapeutics and blockchain technologies for tracking and verifying cannabis genetics. Previously, Kevin was the CSO of Courtagen Life Sciences, Inc., and was Vice President and Director of R&D of Life Technologies where he managed the development of Life Technologies next generation SOLiD sequencing technology. Integral to the SOLiD R&D process, Kevin oversaw over 100 research collaborations exploring the new biological frontiers with next generation sequencing and saw particular excitement and traction in human tumor sequencing. Kevin initiated an R&D project to investigate chemFET semiconductor based DNA sequencing and spearheaded a process to acquire the DNA sequencing company Ion Torrent for $350M. These collaborations resulted in hundreds of publications and 7 Journal covers from Science Translational Medicine to Nature.
Kevin was the President and CSO of Agencourt Personal Genomics, a startup company he co-founded in 2005 to invent revolutionary sequencing technologies that dropped the cost of sequencing a human genome from $300M to $3,000; a 100,000-fold improvement in sequencing speed and cost in a few years. In 2000, Kevin Co-Founded Agencourt Biosciences Corporation and acted as the CSO until it was acquired by Beckman Coulter. Kevin also managed the R&D for the Human Genome Project at Whitehead Institute/MIT resulting in several patents for nucleic acid purification. Kevin holds a B.S. in Biology from Emory University with a focus on cloning and expressing Norepinephrine Transporters. When not decoding DNA and unraveling the mysteries of cannabis medicine, Kevin enjoy boating, skiing, and gardening.
If you like this content, please send a tip with BTC to: 1444meJi7YjgQGNg3U8Z6qYZFA5cgz4Gmj
More Info:
Friends and Sponsors of the Show:
*You have listened to the Tatiana Show. This show may contain adult content, language, and humor and is intended for mature audiences. If that’s not you, please stop listening. Nothing you hear on The Tatiana Show is intended as financial advice, legal advice, or really, anything other than entertainment. Take everything you hear with a grain of salt. Oh, and if you’re hearing to us on an affiliate network, the ideas and views expressed on this show, are not necessarily of the those of the network you are listening on, or of any sponsors or any affiliate products you may hear about on the show.
